Skip to main navigation

Contact Us
Global
- International
- Canada
- France
- Germany
- Italy
- Japan
- Netherlands
- Spain

About Amicus
- About Amicus
- Chairman’s Welcome
- Leadership
- Belief Statement
- Contact Us
- Message from BIO
Patient Advocacy
- Patient Advocacy
- Disease Information
- Rare Stories
- Patient Advisory Boards
- Corporate Giving
- Resources
- Expanded Access
Programs & Pipeline
- Programs & Pipeline
- Our Pipeline
- Fabry Disease
- Pompe Disease
- Batten Disease
- Additional Preclinical Programs
- Clinical Trials
- Platform Technologies
- Journal Articles
- Publications & Posters
Product
- Product
- Galafold^®
- Amicus Assist™
Responsibility
- Responsibility
- Ethics & Compliance
- Global Medical Affairs
- Corporate Giving
- Healing Beyond Disease
- ESG Report
Investors & Media
- Investors & Media
- Investor Relations
- Senior Management Team
- Board of Directors
- Corporate Governance
- Press Releases
- Events & Presentations
- Annual Reports and Proxies
- SEC Filings
- Stock Performance
- Investor FAQs
- Contact Us
- Sign Up for Email Alerts
- Featured Coverage
- Electronic Press Kit
Careers
- Careers
- Overview
- Search

Investors

Press Releases

Press Releases

Year

November 15, 2022

Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference

November 7, 2022

Amicus Therapeutics Provides EU Regulatory Update for AT-GAA

November 7, 2022

Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates

October 28, 2022

U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease

October 27, 2022

Amicus Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022

October 11, 2022

Amicus Therapeutics Announces Participation at World Muscle Society 2022

September 21, 2022

Amicus Therapeutics Announces Participation at the 2022 AANEM Annual Meeting

September 8, 2022

Amicus Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

August 4, 2022

Amicus Therapeutics Announces Second Quarter 2022 Financial Results

July 26, 2022

Amicus Therapeutics to Announce Second Quarter 2022 Financial Results on August 4, 2022

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

About Amicus

Patient Advocacy

Programs & Pipeline

Product
- Overview
- Amicus Assist™

Responsibility

Investors & Media

Careers
- Overview
- Search

Social Media
- Twitter
- YouTube
- LinkedIn

Copyright © 2022 Amicus Therapeutics. All rights reserved. NP-AT-ALL-00011119

Cookies Statement
Terms of Use
Privacy Notice
Privacy Shield Policy

The site you are about to enter is intended for US healthcare professionals.

Please confirm you are a US healthcare professional.

I am a US healthcare professional I am not a US healthcare professional